Chemistry:Batoprotafib
From HandWiki
Batoprotafib (TNO155) is an experimental drug which acts as a selective inhibitor of the protein tyrosine phosphatase enzyme SHP2, which regulates cell growth and differentiation through the MAPK signaling pathway. It is in early stage clinical trials against lung cancer, squamous cell carcinoma and peripheral nerve sheath tumors.[1][2][3][4][5][6]
References
- ↑ "Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer". Journal of Medicinal Chemistry 63 (22): 13578–13594. November 2020. doi:10.1021/acs.jmedchem.0c01170. PMID 32910655.
- ↑ "CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors". Science Advances 9 (47). November 2023. doi:10.1126/sciadv.adg8876. PMID 38000020. Bibcode: 2023SciA....9G8876W.
- ↑ "CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer". Cancer Research 83 (24): 4130–4141. December 2023. doi:10.1158/0008-5472.CAN-23-1127. PMID 37934115.
- ↑ "SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma". Cancer Research Communications 3 (12): 2608–2622. December 2023. doi:10.1158/2767-9764.CRC-23-0234. PMID 38032104.
- ↑ "TNO155 is a selective SHP2 inhibitor to target PTPN11-dependent oral squamous cell carcinoma". Heliyon 10 (21). November 2024. doi:10.1016/j.heliyon.2024.e39677. PMID 39524880. Bibcode: 2024Heliy..1039677C.
- ↑ "The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?". Lung Cancer 194. August 2024. doi:10.1016/j.lungcan.2024.107886. PMID 39047616.
 |  |
